Scarica l'app Stockscreener
25.75
4.28%
-1.278
Precedente Chiudi:
$27.03
Aprire:
$26.99
Volume 24 ore:
226.47K
Relative Volume:
0.25
Capitalizzazione di mercato:
$1.53B
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-13.63
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
-3.13%
1M Prestazione:
+56.53%
6M Prestazione:
+15.77%
1 anno Prestazione:
+17.39%
Intervallo 1D:
$25.76
$27.06
Intervallo di 1 settimana:
$25.50
$28.69
Portata 52W:
$13.30
$29.98
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
25.76 | 1.60B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.76 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.00 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
821.62 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.94 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.26 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Day Trade: What hedge funds are buying TSLA2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock By Investing.com - Investing.com Canada
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics director Heyman sells $32,901 in stock - Investing.com
Why (ELVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Comparing CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN) - Defense World
Stocks To Watch: Enliven Therapeutics Sees RS Rating Jump To 85 - Investor's Business Daily
Will Enliven Therapeutics Inc. stock see insider buyingChart Signals & Short-Term Swing Trade Alerts - bollywoodhelpline.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4%Should You Buy? - MarketBeat
Have Enliven Therapeutics Insiders Been Selling Stock? - Sahm
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. attractive for institutional investorsQuarterly Market Summary & High Return Trade Opportunity Guides - bollywoodhelpline.com
Moving Averages: Does Enliven Therapeutics Inc stock have upside surprise potential2025 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN - Investing.com Canada
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares of Stock - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8%Here's What Happened - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares - Investing.com India
Enliven Therapeutics Insider Sold Shares Worth $3,476,014, According to a Recent SEC Filing - marketscreener.com
Stocks with rising relative price strength: Enliven Therapeutics - MSN
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s Why - Defense World
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data - Sahm
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - FinancialContent
Enliven Therapeutics (NASDAQ:ELVN) Trading 21.1% HigherTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com - Investing.com India
Enliven Therapeutics stock hits 52-week high at $25.64 - Investing.com
Enliven reports positive initial phase 1b data for ELVN-001 in CML - Investing.com Nigeria
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Why Enliven Therapeutics Inc. stock could benefit from AI revolution2025 Earnings Surprises & Growth Focused Entry Point Reports - ulpravda.ru
What risks investors should watch in Enliven Therapeutics Inc. stockWeekly Earnings Recap & Technical Analysis for Trade Confirmation - ulpravda.ru
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data - Yahoo Finance
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Analyst Calls & Long-Term Growth Stock Strategies - Улправда
Is Enliven Therapeutics Inc. stock attractive for hedge fundsTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Enliven touts drug trial results, adds pharma exec to board - bizwest.com
Enliven Therapeutics’ Initial Leukemia Drug Data Excite Investors, Shares Surge - Bitget
Why Is Enliven Therapeutics Stock Soaring Today?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven Stock Soars 51% After Positive CML Trial Results - Nasdaq
How supply chain issues affect Enliven Therapeutics Inc. stock2025 Retail Activity & Free Risk Controlled Daily Trade Plans - Улправда
Shorts Report: How Enliven Therapeutics Inc. stock reacts to oil pricesFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
Enliven surges on trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Enliven Therapeutics Inc Azioni (ELVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Heyman Richard A. | Director |
Jan 20 '26 |
Sale |
26.75 |
1,230 |
32,902 |
23,877 |
3.75%
2.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):